Future Commercialisation Sample Clauses

Future Commercialisation. The project seeks to develop commercial products which are customer driven and include learning from other life science initiatives throughout the UK and internationally. The Highland area has considerable expertise in digital health delivery. It is therefore well placed to harness technology enabled care and to deliver it, at scale, across the region. This unique and agile collaboration will add to this expertise by working with the Highland Innovation and Commercialisation Hub (HI HUB) to create test bed opportunities and open new markets. This project aims to meet all of these challenges by delivering a sustainable and replicable system of housing that includes the technology to enable people to remain in their homes safely and for as long as possible. The project will help reduce hospital admissions, enable people to return from hospital earlier, reduce delays in discharging medically fit patients from hospitals, and provide access for innovative technology into mainstream NHS health delivery. It will contribute to the creation of person-controlled care. See Appendix 6 These houses will be rented as social housing in the first instance. The IT will be developed alongside academic partners. The intellectual property developed as a result of the project will be commercialised using a social enterprise model with profits re-invested in research, development and innovation within the health, housing and care field in partnership with NHS Highland. Any data produced will be managed under strict information governance and will be compliant with the Data Protection Act. Personally identifiable data will only be handled within the health and social care system. NHS Highland has developed a number of techniques that allow the safe passage of person- reported and collected data to enter core e-health systems. We will set up a new company (Sunnd) to take forward the commercial activities and products developed through this project. The company will have a number of commercial arms, reflecting the ownership and legal status of the products being developed. We aim to create social enterprise entities to enable re-investment in health, housing and social care where possible.
Sample 1
AutoNDA by SimpleDocs

Related to Future Commercialisation

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Trials The Ship shall run the following test and trials:

  • Manufacture 2.1. The LED(s) on the LED module shall be equipped with suitable fixation elements.

  • Abuse, Neglect, Exploitation Grantee will;

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Regulatory Approval 25.1 The Parties understand and agree that this Agreement and any amendment or modification hereto will be filed with the Commission for approval in accordance with Section 252 of the Act and may thereafter be filed with the FCC. The Parties believe in good faith and agree that the services to be provided under this Agreement are in the public interest. Each Party covenants and agrees to fully support approval of this Agreement by the Commission or the FCC under Section 252 of the Act without modification.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

Time is Money Join Law Insider Premium to draft better contracts faster.